Pharmaceutical company Sotex has introduced the drug Icatibant Sotex to the Russian market for the treatment of hereditary angioedema (HAE). The medication is expected to become available for sale in September 2025.
Hereditary angioedema (HAE) is a rare, inherited disorder where the body lacks sufficient C1 inhibitor protein, leading to recurrent, severe swelling (angioedema) in areas like the face, extremities, and internal organs.
Icatibant Sotex is approved for use in adult patients and children over the age of two. The subcutaneous injection is designed to halt attacks outside the hospital setting, enabling patients to administer treatment independently during critical episodes, the company stated.
In June, Sotex also launched Destinil, Russia’s first generic sugammadex, a drug used to reverse the effects of neuromuscular blockers during surgical procedures.
